ARMP - Armata Pharmaceuticals, Inc.

8.37
-0.980   -11.708%

Share volume: 27,065
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$9.35
-0.98
-0.10%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
32%
Profitability 35%
Dept financing 43%
Liquidity 22%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.46%
1 Month
-26.71%
3 Months
31.60%
6 Months
183.73%
1 Year
429.75%
2 Year
100.24%
Key data
Stock price
$8.37
P/E Ratio 
N/A
DAY RANGE
$8.25 - $9.09
EPS 
-$4.80
52 WEEK RANGE
$0.90 - $16.34
52 WEEK CHANGE
$473.29
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
36.633 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-06-2025
BETA 
0.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$34,661
AVERAGE 30 VOLUME 
$32,615
Company detail
CEO: Brian C. Varnum
Region: US
Website: armatapharma.com
Employees: 70
IPO year: 2006
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Armata Pharmaceuticals, Inc. focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PS03 for pneumonia.

Recent news